Sanofi and Maze Deal for MZE001 Terminated
Sanofi's agreement with Maze Therapeutics for the development of MZE001 was terminated following an FTC complaint. Explore the implications of this decision.
Topic
Maze Therapeutics
A collection of 8 issues
Maze Therapeutics Announces Profitable IPO Filing
Maze Therapeutics reveals a profit in its IPO filing, planning to list on Nasdaq under 'MAZE'. Discover more about this promising biotech company's financial prospects.
Sanofi Ends Maze Licensing Deal Over FTC Concerns
Sanofi has terminated its global licensing agreement with Maze Therapeutics for Pompe disease treatment, citing issues related to FTC regulations.
Maze and Shionogi Collaborate on Pompe Disease Program
Maze Therapeutics partners with Shionogi to develop a new program targeting Pompe disease. Explore innovative treatments and advancements in genetic disorders.
Maze Therapeutics' Key Advances in Chronic Kidney Disease Therapies
Explore Maze Therapeutics' progress with MZE829 and MZE782, innovative treatments targeting chronic kidney disease. Learn more about these leading programs.
Maze Therapeutics Reports First Profit in 2024 IPO Filing
Maze Therapeutics, backed by Third Rock Ventures, reports its first profit for the first nine months of 2024 in its U.S. IPO filing. Explore Maze Therapeutics' financial growth.
Maze Therapeutics Turns Profitable in 2024
Maze Therapeutics reports a profit for the first nine months of 2024, marking a turnaround from last year's losses. Discover the key factors driving this financial shift.
Biotech IPOs Surge with Strong Performances
Explore the booming biotech IPO market, highlighting successful launches from companies like Maze Therapeutics. Discover key trends and opportunities.